RSS

Neurimmune

An option exercise to further reduce the royalty rates payable on potential future sales of aducanumab — a Phase III investigational treatment for early Alzheimer’s disease — has been announced by Biogen and Neurimmune. more

News

A clinical trial of a new drug shows promising results for those suffering early-stage Alzheimer’s more

News